Search bioRxiv⌕ Search

Biology subjects

LeBlanc, D. P.

Publications and source records attributed to LeBlanc, D. P..

2 recordsLinked to original sources

A robust mutation spectrum analysis framework for high-depth error-corrected sequencing data

Comparing mutational spectra across experimental groups requires inference at the level of the biological replicate. Error-corrected sequencing (ECS) generates hundreds to thousands of mutations per replicate, yet classical pooled G2 tests treat individual mutations as independent observations and ignore replicate-level variability, inflating statistical significance (pseudo-replication). We present a replicate-aware Ridge-Penalized Dirichlet-Multinomial (RP-DMM) framework that models biological replicates directly and accounts for overdispersion. An L2 (ridge) penalty, with strength chosen by leave-one-out cross-validation, stabilizes spectrum estimates by shrinking weakly supported mutation categories toward a common baseline, and inference uses a parametric bootstrap. We also provide a complementary non-parametric rank-permutation test for sparse datasets. In simulations, the pooled G2 test became increasingly anti-conservative as mutation depth increased, with false-positive rates approaching 100% under the null hypothesis. RP-DMM maintained Type I error near the nominal 5% level and had substantially greater power than the rank-permutation test. Regularization was most consequential for high-dimensional spectra. False positive rates approached the nominal 5% level once the lower-mutation group contained approximately 300-500 mutations, depending on the number of biological replicates. A practical target of approximately 400 mutations in the lower-mutation group provided robust Type I error control across all scenarios examined; below this, the rank-permutation test performed robustly and is preferred. In Duplex Sequencing data from benzo[a]pyrene-exposed mice, RP-DMM distinguished exposure-associated mutational signatures from comparisons with higher mutation counts but null effect size, whereas the pooled G2 test declared all comparisons significant. The cross-validated penalty decreased as mutation depth increased, indicating that regularization strength should be tuned to the data. The framework is implemented in the MutSeqR R package.

bioinformatics↗

Duplex Sequencing Provides Detailed Characterization of Mutation Frequencies and Spectra in the Bone Marrow of MutaMouse Males Exposed to Procarbazine Hydrochloride

Mutagenicity testing is an essential component of health safety assessment. Duplex Sequencing (DS), an emerging high-accuracy DNA sequencing technology, may provide substantial advantages over conventional mutagenicity assays. DS could be used to eliminate reliance on standalone reporter assays and provide mechanistic information alongside mutation frequency (MF) data. However, the performance of DS must be thoroughly assessed before it can be routinely implemented for standard testing. We used DS to study spontaneous and procarbazine (PRC)-induced mutations in the bone marrow (BM) of MutaMouse males across a panel of 20 diverse genomic targets. Mice were exposed to 0, 6.25, 12.5, or 25 mg/kg-bw/day for 28 days by oral gavage and BM sampled 42 days post-exposure. Results were compared with those obtained using the conventional lacZ viral plaque assay on the same samples. DS detected significant increases in mutation frequencies and changes to mutation spectra at all PRC doses. Low intra-group variability within DS samples allowed for detection of increases at lower doses than the lacZ assay. While the lacZ assay initially yielded a higher fold-change in mutant frequency than DS, inclusion of clonal mutations in DS mutation frequencies reduced this discrepancy. Power analyses suggested that three animals per dose group and 500 million duplex base pairs per sample is sufficient to detect a 1.5-fold increase in mutations with >80% power. Overall, we demonstrate several advantages of DS over classical mutagenicity assays and provide data to support efforts to identify optimal study designs for the application of DS as a regulatory test.

genomics↗